CTOs on the Move

Cassava Sciences

www.cassavasciences.com

 
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer`s disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

DNA Phenomics

DNA Phenomics is a Bowling Green, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Numira

Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts.   We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening.   Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ever before, saving your team valuable time and resources.

Ontera

Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.

Nereid Therapeutics

Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and resulting biomolecular condensates.

Lantern Pharma

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.